E-scooter hospitalizations up by 40% in past year: CIHI - Global News

IntroductionClimate change is resulting in an increasing frequency of heatwaves, which leads to a substantial increase in deaths and hospitalizations in the summer1. Besides heat, cold continues to be a major health threat and accounts for substantial proportions of deaths2 and hospitalizations3,4. Current evidence suggests heat to be associated with more hospitalizations due to infectious diseases, respiratory, cardiovascular, and neurological outcomes5,6,7, while cold temperatures were primarily associated with cardiovascular and respiratory conditions8. Compared to mortality, hospitalizations reflect a more sensitive indicator of temperature-related health effects, including also less severe cases. Moreover, temperature-related (emergency) hospitalizations are of central public health importance since they naturally reflect unplanned admissions, reveal vulnerabilities in the population, and thus represent a source of uncertainty and potential strain on existing hospital capacity.

Patients with schizophrenia and type 2 diabetes on GLP-1 receptor agonists were less likely to require acute psychiatric care, such as hospital visits, compared with those using other diabetes drugs such as DPP-4 or SGLT2 inhibitors, according to a new peer-reviewed study. The study published on Wednesday in the Lancet Psychiatry journal was based on electronic health record data representing more than 70,200 adults with schizophrenia and T2D who were receiving diabetes therapy between Jan. 1, 2018, and Oct. 1, 2025According to its authors, patients on GLP-1 agonists had a 24% lower risk of undergoing psychiatric hospitalizations compared with those who were not treated for diabetes and an 18% and 17% lower risk compared with those who were on DPP-4 and SGLT2 inhibitors, respectively. Lead investigator Najmeh Davoodian, an associate research fellow at Deakin University in Australia, said that the results marked the first to show a connection between schizophrenia hospitalizations and GLP-1s, a popular drug class marketed by Novo Nordisk NVO and Lilly LLY.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.